SG11202104087QA - Stem cell therapy - Google Patents

Stem cell therapy

Info

Publication number
SG11202104087QA
SG11202104087QA SG11202104087QA SG11202104087QA SG11202104087QA SG 11202104087Q A SG11202104087Q A SG 11202104087QA SG 11202104087Q A SG11202104087Q A SG 11202104087QA SG 11202104087Q A SG11202104087Q A SG 11202104087QA SG 11202104087Q A SG11202104087Q A SG 11202104087QA
Authority
SG
Singapore
Prior art keywords
stem cell
cell therapy
therapy
stem
cell
Prior art date
Application number
SG11202104087QA
Inventor
Diana Hernandez
Original Assignee
Plasticell Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Plasticell Ltd filed Critical Plasticell Ltd
Publication of SG11202104087QA publication Critical patent/SG11202104087QA/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/28—Bone marrow; Haematopoietic stem cells; Mesenchymal stem cells of any origin, e.g. adipose-derived stem cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0647—Haematopoietic stem cells; Uncommitted or multipotent progenitors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/065—Modulators of histone acetylation
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/10—Growth factors
    • C12N2501/125—Stem cell factor [SCF], c-kit ligand [KL]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/10—Growth factors
    • C12N2501/145—Thrombopoietin [TPO]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/26—Flt-3 ligand (CD135L, flk-2 ligand)
SG11202104087QA 2018-10-25 2019-10-24 Stem cell therapy SG11202104087QA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB1817385.6A GB201817385D0 (en) 2018-10-25 2018-10-25 Therapy
PCT/GB2019/053027 WO2020084310A1 (en) 2018-10-25 2019-10-24 Stem cell therapy

Publications (1)

Publication Number Publication Date
SG11202104087QA true SG11202104087QA (en) 2021-05-28

Family

ID=64560526

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11202104087QA SG11202104087QA (en) 2018-10-25 2019-10-24 Stem cell therapy

Country Status (7)

Country Link
US (1) US20210379112A1 (en)
EP (1) EP3870301A1 (en)
JP (1) JP7477520B2 (en)
CN (1) CN113164524A (en)
GB (1) GB201817385D0 (en)
SG (1) SG11202104087QA (en)
WO (1) WO2020084310A1 (en)

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5846958A (en) * 1995-02-17 1998-12-08 U.S. Bioscience, Inc. Methods of using aminothiols to promote hematopoietic progenitor cell growth
WO2004046312A2 (en) * 2002-11-15 2004-06-03 The Board Of Trustees Of The University Of Illinois Methods for in vitro expansion of hematopoietic stem cells
CA2912688C (en) * 2013-05-20 2021-07-13 Icahn School Of Medicine At Mount Sinai Enriched and expanded human cord blood stem cells for treatment of hematological disorders
JP6980534B2 (en) 2015-06-25 2021-12-15 ザ チルドレンズ メディカル センター コーポレーション Methods and Compositions for Enlargement, Enrichment, and Maintenance of Hematopoietic Stem Cells
GB201706544D0 (en) * 2017-04-25 2017-06-07 Plasticell Ltd Method

Also Published As

Publication number Publication date
WO2020084310A1 (en) 2020-04-30
JP2022513391A (en) 2022-02-07
US20210379112A1 (en) 2021-12-09
GB201817385D0 (en) 2018-12-12
CN113164524A (en) 2021-07-23
JP7477520B2 (en) 2024-05-01
EP3870301A1 (en) 2021-09-01

Similar Documents

Publication Publication Date Title
IL282794A (en) Therapeutic methods
SG11202101996QA (en) Improved therapeutic t cell
GB201813178D0 (en) Cell
GB201804255D0 (en) Macrophage-based therapy
GB201803079D0 (en) Cell
GB201701509D0 (en) Pluripotenet stem cells
GB201819853D0 (en) Therapy
EP3802802A4 (en) Cell therapy
GB201900702D0 (en) Therapy
HK1256413A1 (en) Stem cells for wound healing
GB201716408D0 (en) Stem cell microparticles for cancer therapy
GB201805287D0 (en) Haematoietic stem cell treatment
GB2574854B (en) Cell selection procedures
GB201807693D0 (en) Cell
GB201816399D0 (en) Cell
GB201818579D0 (en) New therapy
GB201814036D0 (en) New therapy
GB201805918D0 (en) Cell
SG11202104087QA (en) Stem cell therapy
GB201816934D0 (en) Stem cells
GB201816670D0 (en) Stem cells
GB201911066D0 (en) T cell therapy
GB2577995B (en) Cell
EP4076535A4 (en) Stem cell delivery
GB201820895D0 (en) Therapy